M Virally, JF Blicklé, J Girard, S Halimi, D … - Diabetes and Metabolism, 2007 - Elsevier In France, prevalence of drug-treated diabetes reached 3.60% in 2005, with 92%
of type 2 diabetic patients. In 2007, there are probably nearly 3 000 000
diagnosed or undiagnosed diabetic patients. Ageing of the population and ... Cited by 18 - Related articles - BL Direct - All 2 versions
- ►bmihk.info [PDF] RN Lamounier, JC Pareja, MA Tambascia, B … - Obesity Surgery, 2007 - Springer The digestive tract is well known for its endocrine functions. Recently, many
studies have been reinforc- ing its role as a therapeutic target for both
diabetes and obesity. Losing weight is clinically very difficult for most ... Cited by 12 - Related articles - BL Direct - All 4 versions
EL Kleppinger, K Helms - The Annals of pharmacotherapy, 2007 - Harvey Whitney Books The Annals Visit the journal of Pharmacy Technology for more pharmacy practice
research and reviews! ... Published Online, 24 April 2007, www.theannals.com,
DOI 10.1345/aph.1H460. The Annals of Pharmacotherapy: Vol. 41, No. 5, pp. ... Cited by 5 - Related articles - BL Direct - All 4 versions
N Mikhail - Expert Opin. Investig. Drugs, 2008 - informahealthcare.com Background: Exenatide is an incretin mimetic, while sitagliptin and vildagliptin
are incretin enhancers used as adjunctive therapy in patients with type 2
diabetes failing oral agents. Sitagliptin and vildagliptin can also be used ... Cited by 5 - Related articles - BL Direct - All 9 versions
MA Elrishi, K Khunti, J Jarvis, MJ Davies - Practical Diabetes International, 2007 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 4 - Related articles - BL Direct
G Panina - Diabetes Obes Metab, 2007 - interscience.wiley.com Vildagliptin is a potent selective inhibitor of dipeptidyl peptidase-4 (DPP-4)
that improves glycaemic control by increasing islet α-cell and β-cell
responsiveness to glucose. In patients with type 2 diabetes mellitus ... Cited by 3 - Related articles - All 4 versions
CF Deacon - DIABETES OBESITY AND METABOLISM, 2007 - interscience.wiley.com Incretins are gut peptides that potentiate nutrient-stimulated insulin secretion
following meal ingestion. Activities of the dominant incretins, glucagon-like
peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide, include ... Cited by 3 - Related articles - BL Direct - All 5 versions
HW de Valk - The Review of Diabetic Studies: RDS, 2007 - pubmedcentral.nih.gov The incretin system has proven to be a new source of glucose-lowering drugs.
Glucon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP)
are the incretins which are degraded by dipeptidyl peptidase-4 (DPP-4). ... Cited by 2 - Related articles - All 3 versions
J Rosenstock, M Niggli, M Maldonado- … - Diabetes, Obesity and Metabolism, 2009 - interscience.wiley.com It is also possible that your web browser is not configured or not able to
display style sheets. In this case, although the visual presentation will be
degraded, the site should continue to be functional. We recommend using the ... Cited by 2 - Related articles - All 2 versions
